PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.




PMID- 28373450
OWN - NLM
STAT- MEDLINE
DA  - 20170404
DCOM- 20170413
LR  - 20170413
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 37
IP  - 4
DP  - 2017 Apr
TI  - Human Papilloma Virus-positive Oropharyngeal Squamous Cell Carcinoma in the
      Elderly.
PG  - 1847-1851
AB  - BACKGROUND/AIM: Elderly patients with HPV+ oropharyngeal cancer (OPC) represent
      an understudied cohort of the HPV epidemic. We aimed to investigate the clinical 
      presentation, treatment tolerability and outcomes in patient's >/=65 years old
      with HPV+ OPC. PATIENTS AND METHODS: We identified all patients aged 65 and older
      treated at our Institution with HPV+ OPC and analyzed patient demographics,
      disease characteristics, treatment modalities, toxicities, treatment failures,
      and survival. Charlson comorbidity index was calculated for each patient.
      RESULTS: 43 patients were identified with a mean age of median age was 70.0
      (range 65-86). The mean Charlson comorbidity index score for the cohort was 5.2. 
      In total, 72.1% of patients received what was considered standard-of-care based
      on stage and pathological features. Nine point three percent of patients required
      RT-related treatment breaks with the majority being women (75%). Three-year
      actuarial overall survival was 85.5% (95% CI: 71.4%-100%) and 3-year disease-free
      survival was 67.3% (95% CI: 49.7-91.0%). CONCLUSION: This study presented one of 
      the largest series to date evaluating HPV-related OPC in patients >/=65. Elderly 
      individuals with HPV+ OPC have favorable overall survival with high treatment
      tolerability independent of Charlson co-morbidity score. Elderly patients should 
      be considered for stage-appropriate care with omission of specific therapies
      based on absolute contraindications and patient preference, but not assumptions
      regarding tolerability.
CI  - Copyright(c) 2017, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Dave, Eesha
AU  - Dave E
AD  - Department of Medical Education, Icahn School of Medicine at Mount Sinai, New
      York, NY, U.S.A.
FAU - Su, William
AU  - Su W
AD  - Department of Medical Education, Icahn School of Medicine at Mount Sinai, New
      York, NY, U.S.A.
FAU - Gupta, Vishal
AU  - Gupta V
AD  - Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New
      York, NY, U.S.A.
FAU - Miles, Brett
AU  - Miles B
AD  - Department of Otolaryngology-Head and Neck Surgery, Icahn School of Medicine at
      Mount Sinai, New York, NY, U.S.A.
FAU - Demicco, Elizabeth
AU  - Demicco E
AD  - Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY,
      U.S.A.
FAU - Soriano, Theresa
AU  - Soriano T
AD  - Department of Geriatrics and Palliative Medicine, Icahn School of Medicine at
      Mount Sinai, New York, NY, U.S.A.
FAU - Bakst, Richard L
AU  - Bakst RL
AD  - Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New
      York, NY, U.S.A. [email protected]
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Carcinoma, Squamous Cell/pathology/*virology
MH  - Combined Modality Therapy
MH  - Comorbidity
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Neoplasm Staging
MH  - Oropharyngeal Neoplasms/pathology/*virology
MH  - Papillomaviridae/*isolation & purification
MH  - Papillomavirus Infections/*complications/virology
MH  - Prognosis
MH  - Retrospective Studies
MH  - Survival Rate
OTO - NOTNLM
OT  - *HPV
OT  - *elderly
OT  - *head & neck cancer
EDAT- 2017/04/05 06:00
MHDA- 2017/04/14 06:00
CRDT- 2017/04/05 06:00
PHST- 2017/02/10 [received]
PHST- 2017/03/06 [revised]
PHST- 2017/03/07 [accepted]
AID - 37/4/1847 [pii]
AID - 10.21873/anticanres.11520 [doi]
PST - ppublish
SO  - Anticancer Res. 2017 Apr;37(4):1847-1851.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>